WO2013112676A8 - Schizophrenia-related isoform of knch2 and development of antipsycotic drugs - Google Patents

Schizophrenia-related isoform of knch2 and development of antipsycotic drugs Download PDF

Info

Publication number
WO2013112676A8
WO2013112676A8 PCT/US2013/022878 US2013022878W WO2013112676A8 WO 2013112676 A8 WO2013112676 A8 WO 2013112676A8 US 2013022878 W US2013022878 W US 2013022878W WO 2013112676 A8 WO2013112676 A8 WO 2013112676A8
Authority
WO
WIPO (PCT)
Prior art keywords
schizophrenia
knch2
antipsycotic
drugs
development
Prior art date
Application number
PCT/US2013/022878
Other languages
French (fr)
Other versions
WO2013112676A1 (en
Inventor
Daniel R. Weinberger
Original Assignee
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/357,416 external-priority patent/US8871443B2/en
Application filed by The United States Of America, As Represented By The Secretary, Department Of Health And Human Services filed Critical The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Priority to EP13702565.6A priority Critical patent/EP2807275A1/en
Publication of WO2013112676A1 publication Critical patent/WO2013112676A1/en
Publication of WO2013112676A8 publication Critical patent/WO2013112676A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

The invention is related to a novel primate specific brain isoform of the potassium channel KCNH2 and genetic association with risk for schizophrenia and response to therapy.
PCT/US2013/022878 2012-01-24 2013-01-24 Schizophrenia-related isoform of knch2 and development of antipsycotic drugs WO2013112676A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP13702565.6A EP2807275A1 (en) 2012-01-24 2013-01-24 Schizophrenia-related isoform of knch2 and development of antipsycotic drugs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/357,416 US8871443B2 (en) 2007-03-26 2012-01-24 Schizophrenia-related isoform of KCNH2 and development of antipsychotic drugs
US13/357,416 2012-01-24

Publications (2)

Publication Number Publication Date
WO2013112676A1 WO2013112676A1 (en) 2013-08-01
WO2013112676A8 true WO2013112676A8 (en) 2014-01-23

Family

ID=47633590

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/022878 WO2013112676A1 (en) 2012-01-24 2013-01-24 Schizophrenia-related isoform of knch2 and development of antipsycotic drugs

Country Status (2)

Country Link
EP (1) EP2807275A1 (en)
WO (1) WO2013112676A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3959340A1 (en) * 2019-04-24 2022-03-02 Institut National de la Santé et de la Recherche Médicale (INSERM) Method for predicting the response of antipsychotic drugs

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
EP0730663B1 (en) 1993-10-26 2003-09-24 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US7985551B2 (en) * 2009-11-04 2011-07-26 Suregene, Llc Methods and compositions for the treatment of psychotic disorders through the identification of the SULT4A1-1 haplotype

Also Published As

Publication number Publication date
EP2807275A1 (en) 2014-12-03
WO2013112676A1 (en) 2013-08-01

Similar Documents

Publication Publication Date Title
HK1209793A1 (en) Methods of detecting diseases or conditions
WO2012149299A3 (en) Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
WO2013165921A3 (en) Therapeutic use of chardonnay seed products
SG11201406511VA (en) Catalysts for the production of acrylic acid or its derivatives
BR112014029957A2 (en) processes for producing certain 2- (pyridin-3-yl) thiazoles
GT201400086A (en) COMPOUNDS WITH NEMATICIATED ACTIVITY
WO2008118813A3 (en) Schizophrenia-related isoform of kcnh2 and development of antipsychotic drugs
EP2938616A4 (en) The present invention relates to process for the preparation of tofacitinib and intermediates thereof.
EP2839147B8 (en) Assembly of sections of structural parts
EP2851043A4 (en) Dropper of eye drops
WO2012038975A3 (en) Processes for the preparation of asenapine and intermediates thereof
EP3060681A4 (en) Genetic markers predictive of response to glatiramer acetate
ZA201500228B (en) Ctla4 fusion proteins for the treatment of diabetes
WO2013108105A3 (en) Novel solvates of darunavir
EP2676173A4 (en) Determination of physical parameters associated with erythrocytes
EP3393515A4 (en) Ccl20 as a predictor of clinical response to il23-antagonists
EP2877949A4 (en) Improved clinical effect of pharmaceutical products using communication tool integrated with compound of several pharmaceutical products
WO2013178322A8 (en) Spiro tetrahydro - benzothiophen derivatives useful for the treatment neurodegenerative diseases
EP2925753A4 (en) Novel polymorphs of azilsartan medoxomil
GB201402346D0 (en) Tracking of physiological or medicinal samples
EP3052002A4 (en) Detection of nutrient deficiencies influencing ocular health
WO2012106473A8 (en) Dosing for treatment with anti-egfl7 antibodies
WO2013112676A8 (en) Schizophrenia-related isoform of knch2 and development of antipsycotic drugs
WO2014102759A3 (en) Process for the preparation of dasatinib and its intermediates
EP2842554A4 (en) Broncholytic drug on the basis of prostaglandin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13702565

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2013702565

Country of ref document: EP